Waylivra
The only therapy licensed to treat FCS, as an adjunct to diet in adult patients with genetically confirmed disease and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate (1)
Balancing the challenges of FCS
Living with FCS is a daily challenge
Waylivra is the only therapy licensed to treat FCS, as an adjunct to diet in adult patients with genetically confirmed disease and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate1
Waylivra is an antisense oligonucleotide designed to inhibit the formation of apoC-III1
After 3 months, when added to diet, Waylivra delivered a 77% mean reduction fasting tryglyceride percentage change vs placebo which had a increase of 18 % from baseline1
With proactive monitoring, Waylivra has a safety profile that can be managed1
References
- Waylivra® SmPC